Giada Arancio

Giada Arancio is an endocrine oncologist who has evaluated multiple targeted therapy approaches in adrenocortical carcinoma including sorafenib, sunitinib, and PARP inhibitors including olaparib. She has participated in prospective trials and retrospective analyses demonstrating modest activity of multikinase inhibitors in refractory ACC and has investigated DNA damage repair defects in ACC as a rationale for PARP inhibitor use. She leads studies combining anti-angiogenic targeted therapy with checkpoint inhibition in advanced ACC through ENSAT and Italian oncology consortia.